PMDAsafety guidance83% confidence
[SHINSA]List of therapeutic products for which eligible patients can be identified by Drug-Agnostic CDx,posted
Source: PMDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (nmus rehab) as Study on NMES for Functional Recovery in COPD and Pneumonia Patients.
Regulatory Analysis
PMDA regulatory document relevant to this signal.
Supporting Context
- Therapeutic area
- Respiratory · COPD
- Sub-indication
- Nmus Rehab
Related signal: Study on NMES for Functional Recovery in COPD and Pneumonia Patients